相关实验视频

Updated: Jun 25, 2025

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

口服RDP58改善了DSS诱导的大肠炎在肠道微生物群依赖的方式

Du Zheng¹, Xinlong Ke¹, Huajing Cai¹

¹Department of Anesthesiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, China.

International immunopharmacology

|May 31, 2024

概括

RDP58疗法通过恢复肠道微生物群平衡来改善炎症性肠病 (IBD). 这种治疗增加了有益的短链脂肪酸 (SCFA) 和调节性T细胞 (Tregs),为IBD提供了潜在的新疗法.

科学领域:

胃肠病学胃肠病学
免疫学免疫学免疫学
微生物学微生物学

背景情况:

炎症性肠病 (IBD) 的发病包括肠道微生物群的失衡.
RDP58是一种新,在自身免疫性和炎症性疾病中已证明有效.
在IBD中RDP58的保护作用的机制,特别是它与肠道微生物群的相互作用,需要阐明.

研究的目的:

调查RDP58在硫酸 (DSS) 诱导的大肠炎中的治疗潜力.
阐明RDP58作用的基本机制,重点关注其对肠道微生物群,短链脂肪酸 (SCFA) 和调节性T细胞 (Tregs) 的影响.

主要方法:

通过使用DSS给药来诱导大肠炎的小鼠模型.
通过监测临床症状,结肠炎症标志物和肠道屏障功能来评估治疗效果.
使用16S-rRNA测序分析了肠道微生物组成.
对SCFA和Tregs的水平进行了量化.
进行了抗生素尾酒 (ABX) 和便微生物移植 (FMT) 实验,以证实微生物群依赖的机制.

主要成果:

在小鼠中,RDP58的使用显著改善了DSS诱导的大肠炎.
RDP58治疗改变了肠道微生物群的多样性和组成.
RDP58显著提高了SCFA产生细菌的调节,这反过来又促进了Tregs的产生.
通过ABX和FMT研究证实了机制.

结论:

RDP58证明了对DSS诱导的大肠炎的治疗效果.
保护机制依赖于肠道微生物群的调节,导致SCFA和Treg产量增加.
RDP58提出了一种对IBD有前途的新疗法策略.

关键词:

炎症性肠病 (IBD) 是一种炎症性肠病.微生物群中的微生物群在58年RDP58中,监管性T细胞 (Tregs) 的使用短链脂肪酸 (SCFA) 是一种脂肪酸.

更多相关视频

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

相关概念视频

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...